Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Steven P. Treon, Christian Buske, Sheeba K Thomas, Jorge J. Castillo, Andrew R. Branagan, Meletios A. Dimopoulos, Maria Gavriatopoulou, Diego Cadavid, Felix T Garzon, Weihua Tang, Sean Seyffert, Varun Garg, Shariq Ali, Arthur G. Taveras, Kelly Chen, Jeffrey V. Matous

Blood (2021) 138 (Supplement 1): 1362.

https://doi.org/10.1182/blood-2021-144706

Published: 2021

Journal Articles

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Antonio Garcia-Gomez, Mercedes Garayoa, Enrique M. Ocio, Edvan Crusoe, Diego Fernández, Teresa Paíno, Laura San Segundo, Juan C. Montero, Stela Álvarez-Fernández, Juan F. Blanco, Fermin M. Sanchez-Guijo, Felix T. Garzon, Atanasio Pandiella, Jesús F. San-Miguel, MD, PhD

Blood (2009) 114 (22): 3834.

https://doi.org/10.1182/blood.V114.22.3834.3834

Published: 2009

Journal Articles

Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015).

Kimmo Porkka, MD, Bengt Simonsson, MD, Herve Dombret, MD, Giovanni Martinelli, MD, Oliver G. Ottmann, MD, Chao Zhu, Jan M.A. Van Tornout, MD, Felix T. Garzon, MD, Richard A. Larson, MD

Blood (2007) 110 (11): 2810.

https://doi.org/10.1182/blood.V110.11.2810.2810

Published: 2007

Journal Articles

Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).

Francois Guilhot, MD, Jane F. Apperley, MD, Dong-Wook Kim, MD, Gianantonio Rosti, MD, Xiaobin Yuan, Jan M.A. Van Tornout, MD, Felix T. Garzon, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 470.

https://doi.org/10.1182/blood.V110.11.470.470

Published: 2007

Journal Articles

Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program.

Carlo Gambacorti, Jorge Cortes, Dong-Wook Kim, Herve Dombret, Chao Zhu, Jan M.A. Van Tornout, Felix T. Garzon, Michele Baccarani

Blood (2007) 110 (11): 472.

https://doi.org/10.1182/blood.V110.11.472.472

Published: 2007

Journal Articles

Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study.

Nieves Diaz, MD, Eugeny A. Osmanov, MD, Yulia A. Alexeeva, MD, Mikhail Yu Byakhov, MD, Oleg N. Lipatov, MD, Sergey K. Kravchenko, MD, Ilya S. Zuzgin, MD, Felix T. Garzon, MD, Laurence Elias, MD, Philippe Solal-Celigny, MD.

Blood (2005) 106 (11): 4783.

https://doi.org/10.1182/blood.V106.11.4783.4783

Published: 2005

NARROW

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015).

Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).

Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program.

Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study.

Email alerts

ASH Publications

American Society of Hematology

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015).

Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).

Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program.

Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only